Janssen Pharma Drug Patent Portfolio
Janssen Pharma's Family Patents
Clinical Trials
Recent Clinical Trials by Janssen Pharma:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma | Janssen Pharmaceutical K.K. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | Janssen Pharmaceutica N.V., Belgium | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer | Janssen Pharmaceutical K.K. | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension | Janssen Pharmaceutical K.K. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List